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ABSTRACT
Objective In order to explain the increased
susceptibility to serious infection in alcoholic hepatitis,
we evaluated monocyte phagocytosis, aberrations of
associated signalling pathways and their reversibility, and
whether phagocytic defects could predict subsequent
infection.
Design Monocytes were identiﬁed from blood samples
of 42 patients with severe alcoholic hepatitis using
monoclonal antibody to CD14. Phagocytosis and
monocyte oxidative burst (MOB) were measured ex vivo
using ﬂow cytometry, luminometry and bacterial killing
assays. Defects were related to the subsequent
development of infection. Intracellular signalling
pathways were investigated using western blotting and
PCR. Interferon-γ (IFN-γ) was evaluated for its
therapeutic potential in reversing phagocytic defects.
Paired longitudinal samples were used to evaluate the
effect of in vivo prednisolone therapy.
Results MOB, production of superoxide and bacterial
killing in response to Escherichia coli were markedly
impaired in patients with alcoholic hepatitis.
Pretreatment MOB predicted development of infection
within two weeks with sensitivity and speciﬁcity that
were superior to available clinical markers. Accordingly,
defective MOB was associated with death at 28 and
90 days. Expression of the gp91phox subunit of
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase was reduced in patients with alcoholic hepatitis
demonstrating defective MOB. Monocytes were refractory
to IFN-γ stimulation and showed high levels of a
negative regulator of cytokine signalling, suppressor of
cytokine signalling-1. MOB was unaffected by 7 days in
vivo prednisolone therapy.
Conclusions Monocyte oxidative burst and bacterial
killing is impaired in alcoholic hepatitis while bacterial
uptake by phagocytosis is preserved. Defective MOB is
associated with reduced expression of NADPH oxidase in
these patients and predicts the development of infection
and death.
INTRODUCTION
Alcoholic hepatitis is the most ﬂorid form of alco-
holic liver disease. Severe alcoholic hepatitis (SAH)
develops after heavy and prolonged alcohol
consumption and is associated with high short-term
mortality when Maddrey’s discriminant function
(MDF) is >32.1
Infection is an important contributor to mortal-
ity in SAH. Twenty-ﬁve per cent of patients are
Signiﬁcance of this study
What is already known on this subject?
▸ Infection is common during severe alcoholic
hepatitis (SAH) and can cause death.
▸ Routine prescribing of antibiotics to all patients
with SAH is not advocated, however, and it is,
therefore, important to ﬁnd biomarkers that
can predict the development of infection.
▸ Bacterial killing is effected by innate immune
cells through phagocytosis, but the precise
phagocytic defects that underlie increased
susceptibility to infection remain unclear, with no
studies of monocyte phagocytosis in SAH to date.
▸ Interferon-γ (IFN-γ) has been proposed as a
candidate to reverse neutrophil phagocytic
dysfunction.
What are the new ﬁndings?
▸ Monocytes from patients with SAH are able to
take up Escherichia coli by phagocytosis, but
defective oxidative burst results in impaired
bacterial killing.
▸ Defective monocyte oxidative burst (MOB)
predicted the development of infection within
the subsequent 2 weeks and death by 28 days.
▸ Impaired MOB was associated with reduced
expression of nicotinamide adenine
dinucleotide phosphate oxidase, an enzyme
that generates the superoxide radicals required
for bacterial killing.
▸ Defective MOB could not be reversed by IFN-γ,
and this resistance was associated with
increased expression of the negative regulator
of Janus Kinase-signal transducer and activator
of transcription signalling, suppressor of
cytokine signalling-1.
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admitted with infection, and a further 25% develop nosocomial
infections during their hospital stay.2 Nosocomial infection
more than doubles 60-day mortality in patients treated with cor-
ticosteroids.2 This susceptibility to infection represents an
immune paresis that, as yet, is only partially explained.
Moreover, there is no biomarker currently available that is able
to predict the development of infection in order to guide anti-
biotic prescribing and prevent death from infection in SAH.
Monocytes and neutrophils engulf invading bacteria via
phagocytosis. Phagocytosed bacteria are subsequently killed by
the generation of superoxide radicals (O2
−) in a process known
as oxidative burst. Impairments in circulating neutrophil phago-
cytosis and oxidative burst have been reported in SAH and are
associated with increased mortality.3–5 Neutrophils from patients
with SAH have elevated baseline reactive oxygen species (ROS)
levels4 and reduced phagocytic capabilities.3 5 6 One study sug-
gested that reduced production of the immunostimulatory cyto-
kine interferon-γ (IFN-γ) from T cells is the cause of impaired
neutrophil oxidative burst.6
Interestingly, defective phagocyte oxidative burst is the hall-
mark of the inherited condition chronic granulomatous disease
(CGD), for which prophylactic IFN-γ therapy can reduce the
number of serious infections and hospitalisations.7 However, no
study to date has examined the utility of IFN-γ in improving
phagocyte oxidative burst in SAH. Similarly, no study has exam-
ined the impact of prednisolone therapy on oxidative burst,
despite the common use of this drug as treatment for SAH and
its frequently cited association with nosocomial infection.
Furthermore, although monocyte dysfunction is reported to
contribute to immune paresis in allied liver failure syndromes
such as acute on chronic liver failure and acute liver failure,8–10
there are no data describing monocyte phagocytic capabilities in
SAH.
The present study aims to evaluate phagocytic function of
monocytes during SAH and relate defects to the development of
infection. In addition, the impact of in vivo prednisolone and
the reversibility of ex vivo phagocytic dysfunction with in vitro
IFN-γ were tested.
MATERIALS AND METHODS
Patients and sampling
In total, 101 subjects were recruited to the study from six hospi-
tals in London, UK, between January 2011 and September
2014.
Patients were categorised as follows: 42 patients with SAH;
25 compensated alcohol-related cirrhotic patients, divided into
patients who had been abstinent for at least 6 months (chronic
liver disease [CLD], n=11) and patients who had been actively
drinking within the preceding 6 months (drinking chronic liver
disease [dCLD], n=14); and 34 healthy controls. All patients
with SAH had an alcohol consumption of >80 g/day (men) or
>60 g/day (women) immediately prior to hospital admission;
had bilirubin >80 mmol/L; and MDF ≥32. In addition, patients
with SAH satisﬁed clinical diagnostic criteria described in the
Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) clin-
ical trial protocol.11 In particular, the attending physician con-
trolled any infection with intravenous antibiotics for at least
48 h before entering the patient into the study. These criteria
are listed in online supplementary table S1.
Patients with chronic liver disease were recruited from out-
patient clinics and had cirrhosis diagnosed by previous liver
biopsy or clinical presentation with typical ultrasound or CT
imaging. HC were members of clinical or university staff at St
Mary’s Hospital with no evidence of liver dysfunction.
Deﬁnition of infection
Patients were deemed to have developed infection if any of the
following criteria were met in line with recently published cri-
teria: (i) positive blood cultures; (ii) ascitic neutrophil count
>250 cm−3; (iii) consolidation on chest radiograph in conjunc-
tion with respiratory signs or laboratory markers of infection;
(iv) diarrhoea with positive stool cultures for pathogenic bac-
teria; (v) cellulitis with fever or laboratory signs of infection;
(vi) positive urine culture; (v) intra-abdominal infections: diver-
ticulitis, appendicitis and cholangitis; and (vi) secondary bacter-
ial peritonitis: ascitic neutrophils >250 cm−3 in the presence of
intra-abdominal source of peritonitis and multiple organisms
cultured from ascitic ﬂuid.12
Monocyte phagocytosis and oxidative burst assays
Monocyte oxidative burst (MOB) was assessed ex vivo using the
Phagoburst kit according to the manufacturer’s instructions
(Glycotrope, Germany). In brief, 100uL whole blood was incu-
bated with (test condition) and without (control condition)
2x107 E. coli for 20 min at 37°C. 20 μL 1,2,3-dihydrorhoda-
mine (1,2,3DHR) was then added to each condition for a
further 20 min at 37°C, and the oxidation to rhodamine within
CD14+ monocytes was measured by ﬂow cytometry. Test
responses were compared with control responses in order to
deduce the MOB response to the bacteria. Phagocytosis was
measured using the pHRodo kit (ThermoFisher Scientiﬁc, UK)
according to the manufacturer's instructions.
Monocyte isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinised fresh whole blood after Ficoll density gradient cen-
trifugation according to established protocol.8 Monocytes were
then isolated using the Pan Monocyte Isolation Kit (Miltenyi
Biotec, Germany) according to the manufacturer’s instructions.
A representative ﬁgure illustrating monocyte purity is given in
online supplementary ﬁgure S1.
Monocyte superoxide production
Puriﬁed monocytes were co-cultured for 40 min with E. coli at
a monocyte: E. coli ratio of 1:100. The cell suspension was
then mixed with Diogenes reagent (National Diagnostics, USA)
according to the manufacturer’s instructions and superoxide was
quantiﬁed by recording luminescence (relative light units) using
a luminometer (FLUOstar OPTIMA, BMG Labtech) according
to the manufacturer’s instructions.
Bacterial killing assay
Bacterial killing in supernatant and lysate fractions was measured
as previously described.13 Brieﬂy, isolated monocytes were
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ MOB may be used as a biomarker to predict the
development of infection in patients with SAH and
rationalise prescribing of prophylactic antibiotics.
▸ Targeting defective MOB with molecular or biochemical
techniques may reduce susceptibility to infection and death
in patients with SAH.
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incubated with E. coli (K12, Stratagene) at a 1:100 ratio in
Roswell Park Memorial Institute medium (RPMI) (Sigma, UK)
supplemented with 10% healthy AB serum (Sigma). After
40 min, cooling to 0°C stopped the reaction and supernatants
were aspirated. The monocyte cell pellet was lysed in distilled
water pH 11 according to published literature.14 Supernatant
and lysate fractions were plated separately onto agar plates
(Sigma) at dilutions of 1:10, 1:100 and 1:1000 and colony-
forming units were counted after 18 h incubation at 37°C as pre-
viously described.13
IFN-γ and prednisolone co-culture
PBMCs were incubated for 24 h in RPMI (Sigma) supplemented
with 10% autologous patient serum and 50 ng/mL IFN-γ or
10 μg/mL prednisolone that had been dissolved at 37° for 24 h
prior. The ability of CD14+ monocytes to oxidise 1,2,3-DHR to
rhodamine in response to incubation with E. coli was measured
using modiﬁcations to the ﬂow cytometry-based Phagoburst assay
(Glycotrope).
Western blotting of monocyte G6PDH, pSTAT-1, SOCS-1,
gp91phox and p47phox proteins
Isolated monocytes were rested for 4 h in X-VIVO medium
(Lonza, Switzerland) and then stimulated with 50 ng/mL IFN-γ
for 20 min. Cells were then lysed with ice-cold nonyl
phenoxypolyethoxylethanol-40 buffer (Invitrogen, UK) contain-
ing proteinase inhibitors (Sigma). Protein was separated on
4–12% Bio-Rad gels (Bio-Rad, UK) and transferred to polyviny-
lidene ﬂuoride membranes. Western blotting was performed
using monoclonal antibodies against glucose-6 phosphate
dehydrogenase (G6PDH) (Abcam, UK), gp91phox (Abcam),
phospho-signal transducer and activator of transcription-1
(pSTAT-1) (BD Bioscience, UK), p47phox and Suppressor of
Cytokine Signalling-1 (SOCS-1) (Santa Cruz, USA).
Paired longitudinal samples
Ex vivo MOB was measured before (day 0 MOB) and 7 days
(day 7 MOB) after the start of therapy as determined by the
double-blind randomised design of the STOPAH trial. After
completion of the STOPAH trial, treatment allocation data were
released and used to compare results from patients given oral
prednisolone to patients not given oral prednisolone.
Statistical analysis
Continuous data are expressed as median, IQR or mean (±SD)
as appropriate. The signiﬁcance of differences between medians
or means was tested using Mann–Whitney test or
Wilcoxon-pairs signed rank test for non-parametric data and
paired or unpaired Student’s t tests for parametric data.
Spearman’s rank tests explored correlation. ORs are expressed
with 95% CIs in parentheses. p Values are two-tailed except
where speciﬁed, and p<0.05 was adopted as the threshold for
statistical signiﬁcance. Data were analysed and graphs were
drawn using Prism V.6.0 (GraphPad, USA).
RESULTS
Patient characteristics
Baseline patient and clinical characteristics are summarised in
tables 1 and 2, respectively.
Patients were sampled at a median 5 (3–8) days after admis-
sion to hospital. Therapy was determined by randomisation
within the STOPAH clinical trial in 74% (31/42) of patients and
by clinical judgement in patients not participating in the clinical
trial. In 22 cases, a further follow-up sample was obtained
7 days after the institution of therapy. The types of infection
acquired are given in online supplementary table S2; pneumonia
was the most common and accounted for 59%, followed by
infection of the urinary tract at 18% of all infections.
Phagocytosis of whole bacteria is preserved in SAH
In order to examine phagocytic function of circulating mono-
cytes in SAH, the expression of monocyte surface Fcγ-receptor
CD64 and scavenger receptors (CD36, CD163 and CD206)
were determined. While the expression of scavenger receptors
in SAH was equivalent to HC (ﬁgure 1A–C), expression of
Fcγ-receptor CD64 was increased in SAH compared with
chronic liver disease (CLD) and HC (ﬁgure 1D). Accordingly,
assays using the pHrodo technique showed that monocytes from
patients with SAH were able to phagocytose E. coli as well as
HC (ﬁgure 1E).
MOB and bacterial killing are impaired in SAH
Intracellular killing of internalised bacteria using ROS was quan-
tiﬁed by measuring 1,2,3DHR oxidation to ﬂuorogenic rhoda-
mine. The unstimulated level of ROS production in circulating
monocytes from patients with SAH was similar to that found in
Table 1 Baseline patient characteristics
SAH CLD HC
Age (years) 47 (41–56) 49 (47–56) 42 (36–53)
Male (%) 65 70 30
MELD 24 (22–27) 12 (9–15) n/a
CTP score (class) 10 (C) 7 (B) n/a
INR 1.8 (1.5–2.0) 1.2 (1.2–1.4) n/a
Bilirubin (μmol/L) 318 (200–460) 26 (8–44) n/a
Albumin (g/L) 24 (19–33) 31 (28–36) n/a
White cell count (×109/L) 8.9 (5.6–13.3) 4.9 (3.7–6.1) n/a
Monocyte count (×109/L) 1.0 (0.6–1.5) 0.5 (0.4–0.7) n/a
Neutrophil count (×109/L) 6.9 (3.8–10.3) 2.5 (2.4–3.7) n/a
Alanine transferase (IU/L) 42 (30–79) 21 (17–36) n/a
Aspartate transaminase (IU/L) 127 (100–164) 59 (34–79) n/a
Serum creatinine (μmol/L) 69 (63–104) 63 (57–71) n/a
Median average values (IQR) are shown unless otherwise stated.
CTP, Child-Turcotte-Pugh score; HC, healthy control; INR, international normalised
ratio; MELD, Model for End-Stage Liver Disease; SAH, severe alcoholic hepatitis.
Table 2 Clinical characteristics of severe alcoholic hepatitis study
participants
Maddrey’s discriminant function (IQR) 57 (41–76)
Prednisolone therapy 52% (22/42)
No prednisolone therapy 48% (20/42)
Lille score15 (IQR) 0.4 (0.12–0.65)
Patients receiving antibiotics before initial sampling 50%
Patients with infection* before initial sampling 21%
Patients receiving new or a change of antibiotics within
2 weeks of initial sampling
50%
Patients developing nosocomial infection within 2 weeks of
initial sampling (infected patients*)
40%
28-Day mortality of infected patients* 35%
28-Day mortality of patients who were not infected* 0%
90-Day mortality of infected patients* 63%
90-Day mortality of patients who were not infected* 15%
Values are median average (IQR) unless otherwise stated.
*Infection is defined according to consensus criteria.12
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HC (ﬁgure 2A). However, in response to E. coli, MOB was
markedly impaired in patients with SAH compared with CLD
and HC (ﬁgure 2B). Interestingly, defective MOB was also
noted in actively drinking cirrhotic patients compared with
abstinent cirrhotic patients (ﬁgure 2C).
The impaired ROS generation to E. coli in patients with SAH
corresponded to a speciﬁc reduction in the production of super-
oxide (O2
−) (ﬁgure 2D). Moreover, impaired MOB resulted in
defective intracellular killing of bacteria. Increased numbers of
viable E. coli were enumerated from lysates of monocytes from
patients with SAH compared with HC monocytes (ﬁgure 2E).
In particular, there were more colonies of E. coli enumerated
from the lysates of patients with SAH compared with the corre-
sponding supernatant, a phenomenon not seen in HC, support-
ing the hypothesis of adequate phagocytosis but defective
intracellular bacterial killing in SAH monocytes (ﬁgure 2F).
Defective MOB is associated with increased risk of
developing infection
In view of previous data suggesting that the risk of contracting
infection in SAH is dependent on liver function,2 we explored
the relationship between liver function, systemic inﬂammation
and MOB in patients with SAH.
Prior treatment with systemic antibiotics had no impact on
MOB in patients with SAH (ﬁgure 3A). Day 0 MOB correlated
inversely with white cell count (WCC) (r=−0.5, p=0.001),
C-reactive protein (CRP) (r=−0.4, p=0.01) and procalcitonin
(PCT) (r=−0.37, p=0.02) but there was no correlation with
either static or dynamic markers of liver function such as serum
bilirubin, MDF, Model for End-Stage Liver Disease, early change
in bilirubin level or Lille model.15 In contrast, a strong association
between ex vivo MOB and the subsequent development of infec-
tion within 14 days was detected (ﬁgure 3B). This association
remained statistically signiﬁcant at 90 days (ﬁgure 3C).
SAH MOB had a broad IQR that overlapped that of HC
(580–1832 median ﬂuorescence intensity (MFI) vs 1230–2939
MFI). A range of MOB cut-points were tested and sensitivity
and speciﬁcity values for predicting the development of infec-
tion within 2 weeks at each are given in table 3.
A MOB cut-point at the 50th centile of SAH values had the
greatest sensitivity and speciﬁcity for predicting the develop-
ment of new infection (positive predictive value 0.86 (0.64–
Figure 1 Uptake of bacteria by phagocytosis was similar between severe alcoholic hepatitis (SAH) and healthy monocytes. (A–C) Scavenger
receptor expression was equivalent on SAH monocytes. (D) FcγR expression was increased in SAH compared with healthy control (HC) and CLD; (E)
phagocytosis is preserved in SAH monocytes.
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0.97); area under receiver operating characteristic curve
(AUROC) 0.86 (0.74–0.98; p<0.0001)) (ﬁgure 4A–C). This
was superior to AUROC values for WCC, CRP and PCT (0.75,
0.73 and 0.72, respectively).
The development of new infection within the ﬁrst 2 weeks
was associated with an increased risk of death at 28 and 90 days
(OR 48 (3–918); p<0.0001 and OR 9 (2–46); p=0.003,
respectively). Accordingly, day 0 MOB<50th centile, hereafter
termed MOB defect, was associated with mortality at 28 and
90 days (OR 6.0 and 3.5, one-tailed p=0.044 and 0.041,
respectively).
MOB defect increases susceptibility to catalase-positive
organisms
Bacteria that are able to use the enzyme catalase to defend
against H2O2 mediated attack during phagocyte oxidative burst
are known as catalase-positive organisms. We next sought to
understand whether patients with MOB defect are more suscep-
tible to catalase-positive organisms compared with patients
without MOB defect.
E. coli was the organism grown most frequently by culture,
followed by Candida albicans, and together these two organisms
comprised 50% of all positive cultures (ﬁgure 5A). The majority
Figure 2 Monocyte oxidative burst (MOB) and bacterial killing is impaired in patients with severe alcoholic hepatitis (SAH). (A) The production of
reactive oxygen species (ROS) at rest was similar between SAH and healthy control (HC) monocytes; (B) MOB in response to Escherichia coli is
impaired in SAH compared with HC and CLD; (C) impaired MOB is also seen in cirrhotic patients who were actively drinking at the time of sampling
compared with abstinent cirrhotic patients; (D) impaired MOB corresponded to a reduction in the production of superoxide radicals in response to E.
coli from SAH monocytes; (E) killing of phagocytosed bacteria is reduced in SAH compared with HC monocytes; (F) far more E. coli were enumerated
from the lysate (intracellular fraction) of SAH monocytes compared with the respective supernatant (extracellular fraction).
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of organisms grown by culture in patients with SAH were cata-
lase positive (ﬁgure 5B). All of the catalase-positive organisms
were grown in samples from patients with defective MOB; in
contrast, just 4 of the 8 (50%) samples that grew catalase-
negative organisms came from patients with defective MOB.
Conversely, none of the patients with SAH with MOB >50th
centile were infected by catalase-positive organisms (ﬁgure 5C).
The OR of MOB defect predicting subsequent infection with a
catalase-positive organism was 33 (p=0.007).
In vivo prednisolone therapy does not depress MOB
We sought to determine whether the increased rate of infection
seen in patients treated with prednisolone in the STOPAH
trial16 could be attributed to an effect of prednisolone on MOB.
We, therefore, measured MOB in sequential samples in patients
with SAH treated with or without prednisolone.
In vitro treatment with prednisolone did not alter MOB (E.
coli vs E. coli+prednisolone: 564 vs 458 MFI; p=0.75). This
was conﬁrmed by in vivo data showing that 7 days prednisolone
therapy had no effect on ex vivo phagocytosis or MOB
(ﬁgure 6A, B).
Mechanism of MOB defect
We sought to determine why monocytes from patients with
SAH were unable to an adequate oxidative burst response to
E. coli.
Nicotinamide adenine dinucleotide phosphate substrate
provision
First, we focused on the substrate of the key enzyme nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidase.
Figure 3 Impaired monocyte oxidative burst (MOB) predicts the subsequent development of infection within 2 weeks. (A) Prior prescription of
intravenous antibiotics did not affect severe alcoholic hepatitis (SAH) MOB; (B) patients with SAH who developed infection within 2 weeks of
sampling had a lower pretreatment MOB compared with patients who did not develop infection; (C) patients who developed infection within
90 days of sampling had a lower pretreatment MOB than patients who did not develop infection.
Table 3 Sensitivity and specificity of monocyte oxidative burst for
predicting the subsequent development of infection using a range
of cut-points
Sensitivity (%) Specificity (%)
<25th centile of HC 48 88
<50th centile of SAH 72 82
<25th centile of SAH 100 59
HC, healthy control; SAH, severe alcoholic hepatitis.
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NADPH is required by NADPH oxidase to generate superoxide
and effect bacterial killing. The major source of intracellular
NADPH is from the pentose phosphate pathway, and more spe-
ciﬁcally the G6PDH enzyme. We tested whether G6PDH dys-
function, resulting in inadequate generation of NADPH
substrate, could be the cause of defective MOB.
However, the capacity of intracellular G6PDH in generating
NADPH was equivalent between patients with HC and SAH,
indicating that substrate availability for the NADPH oxidase
enzyme is adequate in monocytes with defective MOB (17 vs
16 nmol/min/mL; p=0.6).
Diminished NADPH oxidase expression in monocytes with
MOB defect
gp-91phox is the major subunit of the NADPH oxidase complex
and p47phox the key regulatory subunit. Intracellular monocyte
expression of gp-91phox and p47phox in patients with SAH was,
therefore, evaluated. Levels of p47phox were equivalent (see
online supplementary ﬁgure S3), but the level of gp91phox in the
monocytes of patients with SAH with MOB defect (SAH
+MOB) was signiﬁcantly reduced compared with patients with
SAH without MOB defect (SAH-MOB) by western blotting,
(ﬁgure 7A). RT-PCR conﬁrmed impaired gene expression of
gp91phox after IFN-γ stimulation in the monocytes of patients
with MOB defect compared with SAH monocytes without
MOB defect (ﬁgure 7B).
SAH monocytes are refractory to IFN-γ, which may be
explained by elevated SOCS-1 protein
IFN-γ is a key cytokine involved in the stimulation of phagocyte
oxidative burst. IFN-γ binding to IFN-γ receptor (IFN-γR)
triggers a Janus Kinase ( JAK) signalling cascade that results in
phosphorylation of STAT-1,17 and activation of the NADPH
oxidase complex. Accordingly, IFN-γ gene knockout renders
mice susceptible to intracellular infections.17 In addition,
patients suffering from CGD, in which mutations in gp91phox
may be inherited, gain effective prophylaxis from opportunistic
infection by treatment with subcutaneous IFN-γ.7 We, therefore,
evaluated whether exogenous IFN-γ administration could
restore defective in vitro MOB in patients with SAH.
Serum levels of IFN-γ and interleukin-12 were similar
between SAH and HC (see online supplementary ﬁgure S2A, B).
Expression of IFN-γR1 was higher on SAH compared with HC
monocytes (1049 vs 928 MFI; p=0.05). However, gene expres-
sion of total STAT-1 in response to IFN-γ was diminished in all
SAH monocytes with or without MOB (ﬁgure 7C). Similarly,
protein expression of activated, phosphorylated STAT-1 with or
without IFN-γ stimulation was reduced in all patients with SAH
(ﬁgure 7D, E).
The JAK-STATsignalling cascade, initiated by IFN-γ binding to
IFN-γR, is negatively regulated by SOCS-1.18 Previously, in vitro
studies from healthy volunteers had shown that high levels of
SOCS-1 can be induced within monocytes in response to alcohol
drinking, potentially rendering monocytes refractory to IFN-γ
stimulation.18 Indeed in the current study, western blots demon-
strated increased expression of this negative intracellular regula-
tor of STAT-1 signalling,17 in SAH monocytes (ﬁgure 7F). It
should be noted that increased SOCS-1 and impaired activation
of STAT-1 was demonstrated in monocytes from all patients with
SAH, regardless of whether there was an MOB defect or not.
Consistent with these ﬁndings, SAH monocytes were resistant to
24 h stimulation with IFN-γ in vitro (ﬁgure 7G).
Figure 4 Monocyte oxidative burst (MOB) <50th centile (MOB defect) can identify patients likely to develop infection more accurately than
conventional clinical markers of infection. (A) Cut-off values at the 50th and 25th centiles of severe alcoholic hepatitis (SAH) MOB and their
association with the development of infection within the subsequent 2 weeks; (B) OR of MOB <50th centile (MOB defect) for predicting infection
within 2 weeks; (C) receiver operating characteristic curve (ROC) curve for MOB and the development of infection within the subsequent 2 weeks;
area under ROC (AUROC) is 0.86 (p<0.0001). For comparison, the ROC curves for C-reactive protein (CRP), white cell count (WCC) and procalcitonin
in predicting the subsequent development of infection are included (AUROC 0.73, 0.75 and 0.72; p=0.019, 0.007 and 0.02, respectively).
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DISCUSSION
In the recent STOPAH trial, 24% of deaths in SAH were attrib-
uted to infection.16 This highlights the importance of infection
and impaired immunity for patients with SAH. The relationship
between the immunodeﬁciency associated with SAH and suscep-
tibility to infection is undoubtedly complex. Our study,
however, reveals that SAH monocytes are characterised by
normal phagocytosis with profoundly impaired oxidative burst
in a subset of patients who are then demonstrably more likely to
contract infection, particularly by catalase-positive organisms.
The results indicate a wide spectrum of oxidative burst cap-
acity in patients with SAH that overlaps the range of oxidative
burst capacity observed in healthy volunteers. This is not sur-
prising, given that there are a substantial proportion of patients
with SAH who do not develop infection. In this regard, we are
particularly encouraged by the close correlation of defective ex
vivo MOB and susceptibility to infection within the subsequent
2 weeks. The strong positive predictive value of MOB for pre-
dicting the development of infection found in the current study
offers a potential biomarker to rationalise prophylactic anti-
biotic prescribing and reduce the incidence of infection in SAH.
Although the data linking defective MOB to susceptibility to
infection are compelling, we are not able to provide direct evi-
dence of causation. The absence of adequate animal models of
Figure 5 Patients with severe alcoholic hepatitis (SAH) with monocyte oxidative burst (MOB) defect are more susceptible to catalase-positive
organisms: (A) organisms grown by culture from patients with SAH recruited to the study; (B) catalase status of organisms grown; (C) susceptibility
of patients with SAH with MOB defect to catalase-positive organisms compared with patients with SAH without MOB defect.
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alcoholic hepatitis is an obstacle to testing such hypotheses, and
in vivo human studies to conﬁrm causation require an agent that
will reliably reverse defective oxidative burst. While IFN-γ is an
attractive therapeutic candidate to restore MOB, data presented
in the current study suggest that the efﬁcacy that this drug has
shown in the treatment of CGD,7 and tuberculosis,19 20 is
unlikely to extend to patients with SAH.
Resistance to interferon therapy that is mediated by SOCS-1
is also seen in hepatocytes infected with hepatitis C virus.21
Elsewhere, elevations in SOCS-1 have been implicated in a
broad range of other persistent intracellular infections including
mycobacterium tuberculosis and group A streptococcus.22–27 In
these infections, the pathogen has evolved to hijack this import-
ant negative regulator of JAK-STAT signalling28 in order to
subvert bacterial killing within the innate immune cell, resulting
in impaired pathogen clearance.
Liver function was found not to correlate with MOB in
patients with SAH. Indeed, the relationship between liver func-
tion and susceptibility to infection in SAH remains controver-
sial.2 Recent clinical studies suggest that susceptibility to
infection in SAH is independent of liver function,29 and our
data of MOB are consistent with this conclusion. Bernsmeier
et al8 showed that, in a group of patients with decompensated
liver disease with similar liver function to patients with SAH but
without alcoholic hepatitis, MOB responses to E. coli were
preserved.
In contrast, the link between alcoholism per se and defective
immunity to facultative intracellular organisms is more estab-
lished.30 Speciﬁcally, infections by bacteria able to use catalase
as a defence against phagocyte oxidative burst, known as
catalase-positive organisms, are known to be prevalent in alco-
holic patients,31–33 and this was veriﬁed in the current study.
The commonest nosocomial infection in recent studies of
patients with SAH is pneumonia, which is often culture nega-
tive. Nosocomial pneumonia is most often caused by
Gram-negative bacilli and Staphylococcus aureus,34 both of
which are catalase-positive organisms. In addition, there appears
to be a preponderance of pneumonia caused by Haemophilus
inﬂuenza and Klebsiella pneumoniae bacteria in alcoholic
patients, both of which are also catalase positive.35 Of note, the
association between alcoholism and the risk of contracting
tuberculosis infection is frequently cited and appears to be inde-
pendent of socio-economic status.36
The molecular cause of this increased incidence of intracellu-
lar infections in alcoholic patients remains elusive, however.
Norkina et al18 found elevations in intracellular monocyte
SOCS-1 and a corresponding decrease in monocyte STAT-1 acti-
vation after healthy volunteers had consumed ethanol. In line
with these data, in the present study we found that alcohol
drinking compensated cirrhotic patients demonstrated defective
MOB but abstinent compensated cirrhotic patients did not. This
suggests that heavy drinking before patients with SAH are
admitted to hospital may contribute to impaired MOB.
Alcohol alone appears insufﬁcient to disrupt MOB, however.
All patients with SAH will have drunk large amounts of alcohol
immediately prior to admission, and yet only a proportion
present with defective MOB. Indeed in the current study,
impaired activation of STAT-1 in SAH monocytes was observed
whether or not the patient displayed an MOB defect ex vivo.
Diminished expression of gp91phox, however, was only demon-
strated in patients with defective MOB. It is likely, therefore,
that impaired IFN-γ signal transduction only partially explains
the observed reduction in gp91phox expression and other
mechanisms, which remain to be identiﬁed, contribute to the
clinical phenotype of impaired oxidative burst and increased
susceptibility to infection.
Seven days of oral prednisolone had no effect on MOB.
Kaufmann et al37 similarly found that in patients suffering from
septic shock neutrophil phagocytosis was unaffected by 24 h
intravenous hydrocortisone therapy. Our study does not, there-
fore, purport to explain the increased incidence of infection
seen in patients treated with prednisolone in the recent
STOPAH trial.
We conclude by noting that in a recent study involving
>700 000 hospitalisations of cirrhotic patients in the USA,
sepsis was the only cause of death that is continuing to rise.38
The defects of phagocytosis in SAH monocytes that have been
demonstrated in the current study are, therefore, pertinent.
Importantly, the mechanism that we have revealed, involving
impaired transduction of IFN-γ signalling and reduced expres-
sion of NADPH oxidase, renders monocytes refractory to
exogenous IFN-γ therapy. Future work should conﬁrm MOB as
a valid biomarker of susceptibility to infection in SAH and iden-
tify molecular targets that are amenable to therapeutic
intervention.
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